December 27, 2023 Sophia Vida
Breaking News

Immutep Advances Towards Phase III Trial for Lung Cancer Treatment with Positive Regulatory Feedback

New York, December 27, 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP), a trailblazing clinical-stage biotechnology company, has announced encouraging news from the Paul-Ehrlich-Institut (PEI), part of the Committee for Medicinal Products for Human Use (CHMP). This announcement marks a significant step forward in the company’s development of novel LAG-3 immunotherapies for cancer and autoimmune diseases. Immutep Limited Marc … Continue reading “Immutep Advances Towards Phase III Trial for Lung Cancer Treatment with Positive Regulatory Feedback”